Genetic engineering of T cells for adoptive immunotherapy

Angel Varela-Rohena, Carmine Carpenito, Elena E. Perez, Max Richardson, Richard V. Parry, Michael Milone, John Scholler, Xueli Hao, Angela Mexas, Richard G. Carroll, Carl H. June, James L. Riley

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations


To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.

Original languageEnglish (US)
Pages (from-to)166-181
Number of pages16
JournalImmunologic Research
Issue number1-3
StatePublished - 2008


  • Adoptive T cell therapy
  • CD28
  • Chimeric immunoreceptor
  • Immunotherapy
  • Lentiviral vector
  • NOG mice
  • PD-1
  • TCR
  • Zinc-finger nuclease

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Genetic engineering of T cells for adoptive immunotherapy'. Together they form a unique fingerprint.

Cite this